Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Company profile
Ticker
CNST
Exchange
Website
CEO
Jigar Raythatha
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Constellation Securities Corporation ...
CNST stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
26 Jul 21
EFFECT
Notice of effectiveness
19 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jul 21
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jul 21
POSASR
Automatic shelf registration (post-effective amendment)
15 Jul 21
POSASR
Automatic shelf registration (post-effective amendment)
15 Jul 21
POS AM
Prospectus update (post-effective amendment)
15 Jul 21
8-K
Completion of Acquisition or Disposition of Assets
15 Jul 21
Latest ownership filings
Financial summary
Quarter (USD) | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm | 117.22 mm |
Cash burn (monthly) | 16.57 mm | 6.14 mm | 13.41 mm | 11.76 mm | 13.25 mm | 10.43 mm |
Cash used (since last report) | 609.61 mm | 225.87 mm | 493.31 mm | 432.64 mm | 487.32 mm | 383.64 mm |
Cash remaining | -492.40 mm | -108.65 mm | -376.09 mm | -315.42 mm | -370.11 mm | -266.42 mm |
Runway (months of cash) | -29.7 | -17.7 | -28.0 | -26.8 | -27.9 | -25.5 |
Institutional ownership, Q1 2023
11.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 131.03 mm |
Total shares | 5.60 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Column Group L P | 2.58 mm | $74.45 mm |
Venrock Associates V | 1.74 mm | $20.00 mm |
Bain Capital Life Sciences Fund | 1.27 mm | $36.58 mm |